The first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with Ruconest (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland. In April 2020, Pharming Group N.V. reported encouraging results [...]
From Intellia Therapeutics, Inc.’s presentation of the financial results for the second quarter of 2020: NTLA-2002 is a wholly owned, in vivo development candidate for the treatment of HAE. Building on Intellia’s modular lipid nanoparticle (LNP) delivery system, NTLA-2002 is designed to knock out the prekallikrein B1 (KLKB1) gene in the liver after a single [...]
“We are currently in an exciting transformation from a company primarily focused on R&D to one that is about to launch its first oral drug to patients with HAE (ORLADEYO) this year. We expect to end the year with ORLADEYO approved in the U.S. and Japan”, says President and CEO Jon Stonehouse, BioCryst Pharmaceuticals, Inc., [...]
Together with the COVID R&D Alliance partners AbbVie, Inc. and Amgen Inc., Takeda Pharmaceutical Co. Ltd. has enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The trial will evaluate the efficacy of a chemokine dual-receptor antagonist, a PDE4 [...]
Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA). Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr. Icatibant injection is indicated for the treatment of acute attacks of HAE in adults 18 years [...]
State and city governments, national patient advocacy groups, and local communities across the United States of America came together on 10 July 2020 to recognize Chronic Disease Day and support the chronic and rare disease communities during a time of unprecedented challenges for individuals who are immunocompromised. Chronic diseases are responsible for seven of the top 10 [...]
Late 2019, HAE International and the non-profit organization of leading clinical and research facilities in the field of allergy and asthma GA2LEN established GA2LEN/HAEi Angioedema Centers of Reference and Excellence – or in short ACARE. The joint venture with GA2LEN fulfills HAE International’s longstanding goal of establishing a worldwide network of accredited angioedema care centers. [...]
It has been almost two and a half years since the idea of the HAEi Youngsters Community was officially launched at the 2018 HAE Global Conference in Vienna, Austria. However, young HAE patients have been connecting online and staying in touch long before that. “At HAE International we are happy to be able to support [...]
No matter if your preferred language is Arabic, Chinese, Greek, Latvian or Spanish there is an Emergency Card from HAE International for you. “As a matter of fact, we are presently at 34 languages and thereby covering a large portion of the globe”, says Henrik Balle Boysen, Executive Vice President & COO of HAE International: [...]
As HAE friends around the globe will know the annual hae day :-) aims to raise awareness worldwide – and as part of the efforts to raise awareness HAE International organizes the HAE Global Walk. “This was also going to be the case in 2020, and we had high expectations regarding setting another record. [...]
